Caley Castelein - 04 Jun 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Reporting relationship: Director
Issuer ticker: TRML
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 16:32:14 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Brad Middlekauff, Attorney-in-Fact

Key filing fact

Caley Castelein filed Form 4 for Tourmaline Bio, Inc. (TRML) on 06 Jun 2025.

Key facts

This page summarizes Caley Castelein's Form 4 filing for Tourmaline Bio, Inc. (TRML).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 16:32.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001355758 Primary reporting owner

Castelein Caley

Relationship: Director
Address: C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK
Signature: /s/ Brad Middlekauff, Attorney-in-Fact
Signature date: 06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRML transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,800
Change %
Price: $0.000000
Shares after: 16,800
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,800
Exercise price: $18.73
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.